Schering-Plough receives data request from Department of Justice over Vytorin, report

In a company regulatory filing, Schering-Plough disclosed that the US Department of Justice has requested information regarding the drugmaker's handling of a study on cholesterol drug Vytorin, which is marketed in partnership with Merck & Co., according to a report in The Wall Street Journal.

US attorneys have made "requests for information" that are similar to previous requests from members of Congress for data and documents about various issues related to the ENHANCE study, the drugmaker noted. Among other information, US lawmakers have asked for documents related to stock sales by Schering-Plough's corporate officers, as well as data on the sale and promotion of Vytorin.

Results from the study, which were released almost two years after the trial was completed, showed that Vytorin was no better than Merck's Zocor alone at slowing atherosclerosis.

To read more Top Story articles, click here.

Reference Articles